News

Hims & Hers Health’s stock booked record losses Monday after Novo Nordisk, maker of the weight-loss drug Wegovy, said it was ...
I am initiating a 'sell' rating on Hims & Hers Health, with a fair value of $35 per share, due to imminent growth risks.
The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...
Novo Nordisk has announced it is ending its distribution collaboration with US telehealth firm Hims & Hers Health over the ...
Novo Nordisk has ended its partnership with Hims & Hers Health after two months, accusing the telehealth company of pushing ...